Roche will pay up to $387 million to license certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.
The National Institutes of Health (NIH) has enlisted the help of 11 top biopharma companies to bring new cancer immunotherapies to patients faster.
The diabetes biotech wants Lilly to pay up $11 million plus extras to offset perceived harm caused by its changes to the product development plan.
Biopharma executives share how they manage outsourcing relationships at this year's Drug Development Forum.
The collaborators will jointly fund a phase 2 trial of the anti-PD-L1 drug-IDO pathway inhibitor combination in pancreatic cancer patients.
Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.
The data monitoring committee ended the trial after ruling it would be futile to keep treating patients with the BMS-partnered Prostvac.
The agreement positions Bristol-Myers to develop subcutaneous formulations of molecules against PD-1 and 10 other immuno-oncology targets.
The deal gives Boehringer access to Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
Janssen is ending a license deal with MacroGenics for duvortuxizumab, a CD19- and CD3-targeting drug for B-cell malignancies.